.@NatureBiotech explored potential of $ADXS's Lm-LLO #immunotherapy tech as a vector to enhance anti-tumor response: http://t.co/Vp1SquSSVD December 2014 issue of Nature Biotechnology. Entitled "Listeria vaccines join the checkpoint frenzy," the article explores the potential of the Listeria bacterium as a vector to enhance an anti-tumor response given its ability to induce powerful innate and adaptive immune responses. Advaxis is featured in the article as one of the leading companies pursuing Listeria-based cancer immunotherapies. Advaxis's Lm-LLO immunotherapy technology is recognized as being unique in the field of immunotherapy drug development in that it uses a live, attenuated bacterial platform genetically engineered to attack cancer tumors and minimize toxicity. In the article, Laurence Wood, Ph.D., assistant professor in the Department of Immunotherapeutics and Biotechnology at the Texas Tech University Health Sciences Center in Abilene, stated that, "Interest from big pharma is a huge deal. Down the road, there will likely be even greater interest in getting bacterial-based cancer vaccines through clinical trials, alone or in combination with other drugs." "One major advantage of Listeria is that it readily gets into and thrives in the cytosol of antigen-presenting cells," adds Dr. Wood in the article. "It is early days, but the revived interest could be warranted. That Listeria based vaccines have shown improved or similar efficacy to standard of care with far fewer adverse events is incredibly promising." Further, the article highlights the observation that Advaxis's Lm-LLO platform is designed in a manner that potentially produces an immune response at a lower dose and makes it easier to combine with other immunotherapy technologies, such as checkpoint inhibitors.